[go: up one dir, main page]

AU7904998A - Pharmaceutical composition containing peptichemio - Google Patents

Pharmaceutical composition containing peptichemio

Info

Publication number
AU7904998A
AU7904998A AU79049/98A AU7904998A AU7904998A AU 7904998 A AU7904998 A AU 7904998A AU 79049/98 A AU79049/98 A AU 79049/98A AU 7904998 A AU7904998 A AU 7904998A AU 7904998 A AU7904998 A AU 7904998A
Authority
AU
Australia
Prior art keywords
peptichemio
pharmaceutical composition
composition containing
pharmaceutical
containing peptichemio
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU79049/98A
Inventor
Francesco Mehlem
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PEPTICHEMIO AG
Original Assignee
PEPTICHEMIO AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PEPTICHEMIO AG filed Critical PEPTICHEMIO AG
Publication of AU7904998A publication Critical patent/AU7904998A/en
Abandoned legal-status Critical Current

Links

Classifications

    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06Tripeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08Tripeptides
    • C07K5/0827Tripeptides containing heteroatoms different from O, S, or N

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Nanotechnology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
AU79049/98A 1997-07-07 1998-07-07 Pharmaceutical composition containing peptichemio Abandoned AU7904998A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CH1651/97 1997-07-07
CH165197 1997-07-07
PCT/CH1998/000300 WO1999002177A1 (en) 1997-07-07 1998-07-07 Pharmaceutical composition containing peptichemio

Publications (1)

Publication Number Publication Date
AU7904998A true AU7904998A (en) 1999-02-08

Family

ID=4215447

Family Applications (1)

Application Number Title Priority Date Filing Date
AU79049/98A Abandoned AU7904998A (en) 1997-07-07 1998-07-07 Pharmaceutical composition containing peptichemio

Country Status (7)

Country Link
US (1) US20030162721A1 (en)
EP (2) EP1001799B1 (en)
JP (1) JP2001509487A (en)
AU (1) AU7904998A (en)
DE (2) DE59801987D1 (en)
IL (1) IL133928A0 (en)
WO (1) WO1999002177A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU758593B2 (en) * 1998-11-19 2003-03-27 Ptc Pharma Ag Method for producing L-prolyl-L-M-sarcolysyl-L-P-fluorophenylalanine and derivatives thereof

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10024451A1 (en) * 2000-05-18 2001-11-29 Asta Medica Ag Pharmaceutical dosage form for peptides, process for their preparation and use
EP1374907A3 (en) * 2002-06-24 2004-01-07 Ghanem Elias c/o Institut Jules Bordet Ghanem Drug transport and delivery system
DE10239832A1 (en) * 2002-08-29 2004-03-18 Lipal Biochemicals AG c/o University of Zurich New sarcolysine derivatives, e.g. amide or peptide compounds, useful as anticancer agents with reduced toxicity to healthy cells
WO2006029385A2 (en) * 2004-09-08 2006-03-16 Chelsea Therapeutics, Inc. Quinazoline derivatives as metabolically inert antifolate compounds.
EP2282740A1 (en) * 2008-04-07 2011-02-16 Chelsea Therapeutics, Inc. Antifolate compositions
KR101522918B1 (en) 2009-05-29 2015-05-27 사이덱스 파마슈티칼스, 인크. Injectable melphalan compositions comprising a cyclodextrin derivative and methods of making and using the same
US11020363B2 (en) 2009-05-29 2021-06-01 Cydex Pharmaceuticals, Inc. Injectable nitrogen mustard compositions comprising a cyclodextrin derivative and methods of making and using the same
WO2011005832A1 (en) * 2009-07-08 2011-01-13 Chelsea Therapeutics, Inc. Stable crystalline polymorphs of the dipotassium salt of (s) -2- {4- [2- (2, 4-diamin0-quinaz0lin-6-yl) -ethyl] -benzoylamino} -4-methylenξ-penta nedioic acid
KR20120103604A (en) * 2009-11-06 2012-09-19 첼시 쎄라퓨틱스, 인코포레이티드 Enzyme inhibiting compounds
WO2012064377A1 (en) * 2010-03-29 2012-05-18 Chelsea Therapeutics, Inc. Antifolate compositions
US8658652B2 (en) 2010-12-07 2014-02-25 Chelsea Therapeutics, Inc. Antifolate combinations
US10975121B2 (en) 2017-06-24 2021-04-13 Cytogel Pharma, Llc Analgesic mu-opioid receptor binding peptide pharmaceutical formulations and uses thereof
CN111683654A (en) * 2017-11-30 2020-09-18 细胞凝胶制药有限责任公司 Novel analgesic pharmaceutical preparation and use thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2094175A1 (en) * 1970-06-11 1972-02-04 Istituto Sieroterapic Antitumour oligopeptides - contg meta-(di-(2-chloroethyl)-amino)-l-ph
US3814746A (en) * 1970-08-05 1974-06-04 Inst Sieroterapico Milanese Se Mannich base of tetracycline and polypeptides
CA2134753A1 (en) * 1993-03-08 1994-09-15 Peter K. Chiang Cyclodextrin-peptide compositions

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU758593B2 (en) * 1998-11-19 2003-03-27 Ptc Pharma Ag Method for producing L-prolyl-L-M-sarcolysyl-L-P-fluorophenylalanine and derivatives thereof

Also Published As

Publication number Publication date
EP1001799B1 (en) 2001-10-31
EP1132395A3 (en) 2002-02-06
EP1132395A2 (en) 2001-09-12
EP1001799A1 (en) 2000-05-24
JP2001509487A (en) 2001-07-24
EP1132395B1 (en) 2003-10-29
WO1999002177A1 (en) 1999-01-21
DE59801987D1 (en) 2001-12-06
IL133928A0 (en) 2001-04-30
US20030162721A1 (en) 2003-08-28
DE59810043D1 (en) 2003-12-04

Similar Documents

Publication Publication Date Title
AU6740298A (en) Pharmaceutical composition
AU8107998A (en) Pharmaceutical compositions
AU8591898A (en) Pharmaceutical compounds
AU7904998A (en) Pharmaceutical composition containing peptichemio
AU5155096A (en) Pharmaceutical composition
AU2531295A (en) Pharmaceutical composition
GB9717444D0 (en) Pharmaceutical composition
HUP0002455A3 (en) Gastric-retained pharmaceutical composition
AU9343098A (en) Pharmaceutical composition
AU1044799A (en) Pharmaceutical composition containing zafirlukast
AUPP332898A0 (en) Pharmaceutical composition
AU1172097A (en) Pharmaceutical composition containing trehalose
AU1509799A (en) Pharmaceutical composition containing cyclosporin
AU8817498A (en) Pharmaceutical composition containing midazolam
GB2321190B (en) Pharmaceutical composition
AU6814496A (en) Pharmaceutical composition
GB9726781D0 (en) Pharmaceutical composition
AUPO590197A0 (en) Pharmaceutical composition
AUPO598497A0 (en) Pharmaceutical composition
AU7826198A (en) Pharmaceutical compositions containing alpha-tocopherylphosphocholine
AUPO597997A0 (en) Medicinal composition
AUPO833297A0 (en) Pharmaceutical compositions
AU723097C (en) Pharmaceutical composition
AU741226C (en) Pharmaceutical composition
AUPN890796A0 (en) Pharmaceutical composition

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase